#None #Vienna #CGM #diabetes #SIBIONICS

SiBionics Shines at EASD 2025: A Leap in Diabetes Management

SiBionics, a leading name in healthcare technology, made a significant impact at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Vienna. Their flagship solutions, the Continuous Glucose Monitoring (CGM) system GS3 combined with the Continuous Ketone Monitoring (CKM) system KS3, were the focal points of attention at the event. Recognized for their innovative approach, these integrated solutions have garnered widespread acclaim from researchers and healthcare professionals across the globe.

The EASD Symposium: A Platform for Dialogue

The symposium organized by SiBionics, entitled "CGM + CKM for Enhanced Diabetes Management," featured prominent figures in the field, including co-chairs Professor Linong Ji from Peking University People's Hospital and Professor Stefano Genovese from Italy. Notable speakers such as Professor Andrej Janež from Slovenia, Professor Nina Jendrike from Germany, and Dr. Yifei Mo from China contributed their insights on the latest research outcomes, igniting discussions on the vast potentials of SiBionics' innovations.

Attention-Grabbing Exhibition

Visitors to the exhibition were captivated by the advanced features of the SiBionics devices. The GS3 and KS3 systems attracted considerable attention for their technological capabilities and clinical relevance. Attendees engaged in meaningful conversations with the SiBionics team, seeking to understand the practical applications of these tools in diabetes care and management.

Exceeding Standards: A Promise of Efficiency

The recent feasibility study presented by SiBionics confirmed that their CGM system meets and even surpasses the iCGM standards across various key performance indicators. It showcased remarkable accuracy, particularly within hypoglycemic ranges, which is critical for effective clinical decision-making and patient self-monitoring. These advancements affirm SiBionics' commitment to enhancing diabetes care through technology.

Leading the Charge in Continuous Monitoring Technology

SiBionics is currently at the forefront of continuous monitoring technology and stands out as the only company worldwide commercializing CKM systems. Their innovative vision and robust R&D capabilities position them to significantly influence how diabetes is managed. The company is dedicated to expanding its CXM systems portfolio and driving innovation in the field.

The Future of Diabetes Management

Looking ahead, SiBionics aims to enhance treatment outcomes for diabetic patients globally. Founded in 2015, the company, with headquarters in Shenzhen and Irvine, specializes in developing medical equipment that integrates biological sensors, intelligent algorithms, and user-friendly software. With a workforce of over 500 — 25% dedicated to research and development — SiBionics is at the helm of personalized healthcare driven by data.

As SiBionics continues to push boundaries in diabetes management technology, the outcomes of their innovative approaches at the EASD 2025 are set to revolutionize how diabetes care is approached worldwide.